A Randomized, Double-Blind Study of the Efficacy and Safety of Oral Ganciclovir for the Prevention of CMV Disease in People Infected With the Human Immunodeficiency Virus

NACompletedINTERVENTIONAL
Enrollment

700

Participants

Timeline

Start Date

Not specified

Conditions
Cytomegalovirus InfectionsHIV Infections
Interventions
DRUG

Ganciclovir

Trial Locations (19)

10016

Kaplan Cancer Ctr / New York Univ Med Ctr, New York

10019

St Lukes - Roosevelt Hosp Ctr, New York

10021

Cornell Univ Med College / New York Hosp, New York

15261

Univ of Pittsburgh / Graduate School of Public Health, Pittsburgh

19107

Buckley Braffman Stern Med Associates, Philadelphia

20007

Georgetown Univ Med Ctr, Washington D.C.

30308

AIDS Research Consortium of Atlanta, Atlanta

33146

Community Research Initiative, Coral Gables

60612

Rush Presbyterian - Saint Luke's Med Ctr / Rush Med Coll, Chicago

75219

Oak Lawn Physicians Group, Dallas

77030

Infectious Diseases Association of Houston, Houston

90028

Kraus - Beer Med Group, Los Angeles

90502

Harbor - UCLA Med Ctr, Torrance

92103

UCSD, San Diego

94114

Davies Med Ctr / c/o HIV Institute, San Francisco

94115

Mount Zion Med Ctr, San Francisco

94121

San Francisco Veterans Administration Med Ctr, San Francisco

94705

East Bay AIDS Ctr, Berkeley

02215

Beth Israel Hosp, Boston

All Listed Sponsors
lead

Hoffmann-La Roche

INDUSTRY

NCT00002095 - A Randomized, Double-Blind Study of the Efficacy and Safety of Oral Ganciclovir for the Prevention of CMV Disease in People Infected With the Human Immunodeficiency Virus | Biotech Hunter | Biotech Hunter